Abivax S.A. Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
Abivax S.A. (ABVX) reported Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of -EUR 84.39 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2026-03-23
- Abivax S.A. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2025-12-31 was -30.97M EUR.
- Abivax S.A. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2025-09-30 was -46.42M EUR.
- Abivax S.A. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2025-06-30 was -7.00M EUR.
- Abivax S.A. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2025-03-31 was -5.37M EUR.
| Period end | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 3 month | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 6 month | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 9 month | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | -30.97M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-03-23 | -77.39M EUR derived: sum of 2 quarters · filed 2026-03-23 | -84.39M EUR derived: sum of 3 quarters · filed 2026-03-23 | -84.39M EUR 20-F · filed 2026-03-23 |
| 2025-09-30 | -46.42M EUR 6-K · filed 2025-12-15 | -53.41M EUR derived: sum of 2 quarters · filed 2025-12-15 | -53.41M EUR 6-K · filed 2025-12-15 | -63.34M EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-06-30 | -7.00M EUR 6-K · filed 2025-09-08 | -12.37M EUR 6-K · filed 2025-09-08 | -16.93M EUR derived: sum of 3 quarters · filed 2026-03-23 | -27.47M EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-03-31 | -5.37M EUR 6-K · filed 2025-06-02 | -9.93M EUR derived: sum of 2 quarters · filed 2026-03-23 | -20.47M EUR derived: sum of 3 quarters · filed 2026-03-23 | -26.31M EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2024-12-31 | -4.55M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-03-23 | -15.10M EUR derived: sum of 2 quarters · filed 2026-03-23 | -20.94M EUR derived: sum of 3 quarters · filed 2026-03-23 | -20.94M EUR 20-F · filed 2026-03-23 |
| 2024-09-30 | -10.54M EUR 6-K · filed 2025-12-15 | -16.39M EUR derived: sum of 2 quarters · filed 2025-12-15 | -16.39M EUR 6-K · filed 2025-12-15 | |
| 2024-06-30 | -5.84M EUR 6-K · filed 2025-09-08 | -12.06M EUR 6-K · filed 2025-09-08 | ||
| 2024-03-31 | -6.22M EUR 6-K · filed 2025-06-02 | |||
| 2023-12-31 | -8.61M EUR 20-F · filed 2026-03-23 | |||
| 2022-12-31 | -1.37M EUR 20-F · filed 2025-03-24 | |||
| 2021-12-31 | 1.03M EUR 20-F · filed 2024-04-05 |